Merck — partners with Moderna on mRNA-4157/V940 and supplies the pembrolizumab (Keytruda) checkpoint backbone across many vaccine combinations.
Merck (MSD) and Moderna are advancing individualized neoantigen therapies, leveraging next-gen sequencing and deterministic algorithms to target unique tumor mutations. This sponsored content underscores the industry shift toward precision medicine that accounts for the genomic randomness driving distinct patient responses to cancer treatments.
[ACTIVE_NOT_RECRUITING · PHASE3 · Merck Sharp & Dohme LLC] The purpose of this study is to learn if intismeran autogene which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid \[mRNA\]-4157) with pembrolizumab (MK-3475) is safe and prevents…
Merck Sharp & Dohme has terminated the Phase 2/3 V940-007 trial evaluating intismeran autogene (V940) plus pembrolizumab in locally resectable advanced cutaneous squamous cell carcinoma. The termination halts the development of this personalized neoantigen therapy in this specific indication, though the parallel Phase 3 melanoma study (NCT05933577) remains active and not yet recruiting.
Moderna and Merck have released five-year follow-up data for their personalized cancer vaccine candidate combined with KEYTRUDA in melanoma, demonstrating durable clinical benefit. This long-term efficacy signal is critical for validating the neoantigen vaccine platform's ability to sustain immune responses and improve survival outcomes in advanced disease.
Merck explores the concept of 'one medicine for one patient' in individualized neoantigen therapies. As a major payer and partner in the space, Merck’s framing highlights the logistical and economic challenges of personalization that industry must solve for widespread adoption.
Merck provides an overview of individualized neoantigen therapies, likely defining the standard of care or technological requirements for the sector. This educational content from a key industry participant helps standardize market understanding and investment theses.